InMed Pharmaceuticals is pleased to welcome the BayMedica team following the acquisition in October 2021.
Meet Chris Meiering, our VP of Commercial Operations. Chris talks about the unique start to his career in pet nutrition and how he got into the business of developing rare cannabinoids for the health and wellness sector.
Chris earned his PhD in microbiology, specializing in molecular virology, from the University of Washington and performed his post doctoral research at Stanford University.
A peer-reviewed scientific study entitled “Rare phytocannabinoids exert anti-inflammatory effects on human keratinocytes via the endocannabinoid system and MAPK signalling pathway” has been published in the International
InMed’s CEO, Mr. Eric A. Adams, presents at the Emerging Growth Conference. This virtual presentation was given on March 8th, 2023. In the presentation, Mr.
InMed’s Senior VP, Preclinical Research and Development, Dr. Eric Hsu, shares results from early neurodegenerative disease studies demonstrating how specific cannabinoids induced neuroprotective effects and
© Copyright 2023 InMed Pharmaceuticals Inc.
"*" indicates required fields